HERmark Breast Cancer Assay precisely quantifies HER-2 total protein levels in formalin-fixed parrafin-embedded (FFPE) tissue. The assay performance characteristics are validated according to CLIA standards. HERmark results provide health care professionals with additional information for managing breast cancer patients.
Monogram offers proprietary VeraTag technology for oncology and is a fully quantitative HER-2 protein test. VeraTag technology provides pharmaceutical partners and academic collaborators with sensitive and quantitative measurements of cell-surface receptors and activated proteins and complexes in cancer cell lines, xenografts, and multiple solid tumor types.